Publications by authors named "William Sharfman"

Claim this Profile
P
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stability.
Yujie Zhao, Jarushka Naidoo, Michael Conroy, Jacqueline T Ferri, Joell J Gills, William H Sharfman

medRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.
Shailender Bhatia, Suzanne L Topalian, William Sharfman, Tim Meyer, Neil Steven

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related encephalitis after immune checkpoint inhibitor therapy.
Monica W Buckley, Aanika Balaji Warner, Julie Brahmer, Laura C Cappelli, William H Sharfman

Oncologist· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
Ana Oaknin, Kathleen Moore, Tim Meyer, José López-Picazo González, Lot A Devriese, William H Sharfman

Lancet Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, William H Sharfman

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Nikhil I Khushalani, Patrick A Ott, Robert L Ferris, Tina Cascone, Dirk Schadendorf, William Sharfman

J Immunother Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
Julie R Brahmer, Charles G Drake, Ira Wollner, John D Powderly, Joel Picus, William H Sharfman

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, William H Sharfman

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bing-Neel syndrome.
Katelynn Davis, William H Sharfman, Ivo M B Francischetti

EJHaem· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma.
Merve Hasanov, Denái R Milton, William H Sharfman, Bret Taback, Lee D Cranmer

Oncoimmunology· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Robert L Ferris, William C Spanos, Rom Leidner, Anthony Gonçalves, Uwe M Martens, William Sharfman

J Immunother Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Paul Nghiem, Shailender Bhatia, Evan J Lipson, William H Sharfman, Ragini R Kudchadkar

J Immunother Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
Shrinivas Bishu, Joanna Melia, William Sharfman, Christopher D Lao, Leslie A Fecher

Gastroenterology· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
F Stephen Hodi, Paul B Chapman, Mario Sznol, Christopher D Lao, Rene Gonzalez, William Sharfman

Melanoma Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodriguez, Petra Ross-Macdonald, William Sharfman

Cancer Cell· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodriguez, Petra Ross-Macdonald, William Sharfman

Cancer Cell· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
Suzanne L Topalian, Shailender Bhatia, Asim Amin, Ragini R Kudchadkar, William H Sharfman

J Clin Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.
Jaclyn LoPiccolo, Megan D Schollenberger, Sumia Dakhil, Samuel Rosner, Osama Ali, William H Sharfman

J Immunother Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
Paul Nghiem, Shailender Bhatia, Evan J Lipson, William H Sharfman, Ragini R Kudchadkar

J Clin Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.
Kellie N Smith, Nicolas J Llosa, Tricia R Cottrell, Nicholas Siegel, Hongni Fan, William H Sharfman

J Immunother Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.
Kellie N Smith, Nicolas J Llosa, Tricia R Cottrell, Nicholas Siegel, Hongni Fan, William H Sharfman

J Immunother Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting.
Steven P Rowe, Brandon Luber, Monique Makell, Patricia Brothers, JoAnn Santmyer, William H Sharfman

Mol Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.
Kendall F Moseley, Jarushka Naidoo, Clifton O Bingham, Michael A Carducci, Patrick M Forde, William H Sharfman

J Immunother Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells.
Yuanxuan Xia, Leila A Mashouf, Russell Maxwell, Luke C Peng, Evan J Lipson, William H Sharfman

Surg Neurol Int· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Ryan J Sullivan, Michael B Atkins, John M Kirkwood, Sanjiv S Agarwala, Joseph I Clark, William Sharfman

J Immunother Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis